Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NDAC in '01

This article was originally published in The Tan Sheet

Executive Summary

Tentative Dec. 7-8 meeting cancelled; next scheduled meeting date is May 10-11, 2001. NDAC evaluated five subjects in 2000. In July, the committee considered issues related to the relaunch of the Today Sponge by Allendale Pharmaceuticals and the Rx-to-OTC switch applications for cholesterol-lowering statin drugs Mevacor (Merck) and Pravachol (Bristol-Myers Squibb). In October, NDAC met to discuss phenylpropanolamine use in cough/cold and weight loss products, as well as AstraZeneca/P&G's switch application for the proton pump inhibitor Prilosec
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS091961

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel